Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration Sensitive Prostate Cancer”

150 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 150 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06134271
What this trial is testing

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Jianbin Bi 160
Testing effectiveness (Phase 2)Study completedNCT01875250
What this trial is testing

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 38
Large-scale testing (Phase 3)Active Not RecruitingNCT02489318
What this trial is testing

Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Who this might be right for
Prostate Cancer
Aragon Pharmaceuticals, Inc. 1,052
Large-scale testing (Phase 3)Looking for participantsNCT03903835
What this trial is testing

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet 750
Not applicableActive Not RecruitingNCT06010914
What this trial is testing

Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Bayer 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04076059
What this trial is testing

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma China, Inc. 180
Not applicableStudy completedNCT07086651
What this trial is testing

Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate Neoplasms+1 more
Pfizer 1,300
Testing effectiveness (Phase 2)Active Not RecruitingNCT05241860
What this trial is testing

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8+2 more
Alliance for Clinical Trials in Oncology 79
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07268794
What this trial is testing

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fudan University 112
Testing effectiveness (Phase 2)Looking for participantsNCT07005154
What this trial is testing

Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 218
Early research (Phase 1)Ended earlyNCT05733351
What this trial is testing

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Emory University 4
Large-scale testing (Phase 3)Study completedNCT02799602
What this trial is testing

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 1,306
Not applicableUnknownNCT02723526
What this trial is testing

Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Fudan University 100
Early research (Phase 1)Not Yet RecruitingNCT07339267
What this trial is testing

Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 12
Large-scale testing (Phase 3)Looking for participantsNCT05983783
What this trial is testing

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Who this might be right for
Metastatic Prostate CancerHormone Sensitive Prostate CancerChemotherapy Effect
The First Affiliated Hospital with Nanjing Medical University 200
Large-scale testing (Phase 3)Looking for participantsNCT06592924
What this trial is testing

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Canadian Cancer Trials Group 830
Not applicableLooking for participantsNCT06652607
What this trial is testing

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Who this might be right for
Prostate CancerMetastatic CancerCastrate Sensitive Prostate Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 152
Large-scale testing (Phase 3)UnknownNCT03879122
What this trial is testing

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Spanish Oncology Genito-Urinary Group 135
Large-scale testing (Phase 3)Active Not RecruitingNCT05288166
What this trial is testing

Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Who this might be right for
Prostatic NeoplasmsNeoplasm MetastasisUrogenital Neoplasms+14 more
Eli Lilly and Company 925
Large-scale testing (Phase 3)Ended earlyNCT04409288
What this trial is testing

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Chinese University of Hong Kong 74
Load More Results